Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck's HPV vaccine Gardasil 9 meets efficacy goals in trial involving Japanese males 16-26 years old, reducing HPV ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company’s ...

The global lipid nanoparticles market is expected to grow from USD 271.8 million in 2024 to USD 350.5 million by 2029, with a ...

According to GlobalData, the recombinant vesicular stomatitis virus – Zaire Ebola virus (rVSV-ZEBOV) vaccine is marketed by Merck under the name Ervebo. It has been available in the US and EU ...

Merck's strong entrenchment in vaccines adds a layer of competitive protection from intellectual property and cost advantages, as the company's large-scale production enables a lower cost base ...